|
C11ORF54 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85296222809939E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.04260053315863E-10 |
| Normal-vs-Stage2 |
2.83590000371703E-08 |
| Normal-vs-Stage3 |
1.79349868290046E-11 |
| Normal-vs-Stage4 |
1.79256609555978E-12 |
| Stage1-vs-Stage2 |
2.143800E-01 |
| Stage1-vs-Stage3 |
5.140400E-02 |
| Stage1-vs-Stage4 |
6.006900E-04 |
| Stage2-vs-Stage3 |
8.609200E-01 |
| Stage2-vs-Stage4 |
2.069400E-01 |
| Stage3-vs-Stage4 |
1.656150E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.72084568816899E-13 |
| Normal-vs-AfricanAmerican |
5.837300E-04 |
| Normal-vs-Asian |
3.21899999988773E-08 |
| Caucasian-vs-AfricanAmerican |
2.889200E-01 |
| Caucasian-vs-Asian |
6.736600E-01 |
| AfricanAmerican-vs-Asian |
5.387000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.11812814352197E-14 |
| Normal-vs-Female |
2.42079689627417E-11 |
| Male-vs-Female |
2.626000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.91659998561545E-09 |
| Normal-vs-Age(41-60Yrs) |
5.46569456361112E-11 |
| Normal-vs-Age(61-80Yrs) |
1.64790403545112E-12 |
| Normal-vs-Age(81-100Yrs) |
2.842300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.109200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.736300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.722200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.754180E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.233200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.402800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.739500E-02 |
| Classical-VS-Follicular |
4.202000E-01 |
| Classical-VS-Other |
6.298200E-01 |
| Classical-VS-Normal |
1.7647994177139E-11 |
| Tall-VS-Follicular |
3.152200E-01 |
| Tall-VS-Other |
6.635400E-01 |
| Tall-VS-Normal |
7.97330002022534E-09 |
| Follicular-VS-Other |
8.811000E-01 |
| Follicular-VS-Normal |
1.611699995685E-08 |
| Other-VS-Normal |
4.064500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22389876011653E-11 |
| Normal-vs-N1 |
3.93740040571799E-10 |
| N0-vs-N1 |
4.196200E-01 |
|
|
